ARTICLE
27 September 2023

FTC Sues Private Equity Firm And Anesthesiology Practice For Antitrust Violations

SM
Sheppard Mullin Richter & Hampton

Contributor

Sheppard Mullin is a full service Global 100 firm with over 1,000 attorneys in 16 offices located in the United States, Europe and Asia. Since 1927, companies have turned to Sheppard Mullin to handle corporate and technology matters, high stakes litigation and complex financial transactions. In the US, the firm’s clients include more than half of the Fortune 100.
On September 21, 2023, the Federal Trade Commission (FTC) sued Welsh, Carson, Anderson & Stowe (WCAS) and U.S. Anesthesia Partners, Inc. (USAP), in the Southern District of Texas...
United States Texas Antitrust/Competition Law
To print this article, all you need is to be registered or login on Mondaq.com.

On September 21, 2023, the Federal Trade Commission (FTC) sued Welsh, Carson, Anderson & Stowe (WCAS) and U.S. Anesthesia Partners, Inc. (USAP), in the Southern District of Texas, alleging the two companies "[e]xecuted a multi-year anticompetitive scheme to consolidate anesthesiology practices in Texas, drive up the price of anesthesia services provided to Texas patients, and boost their own profits."

According to the FTC's complaint, WCAS founded USAP in 2012 to execute a strategy to consolidate hospital-based anesthesiology services in Texas, including by acquiring large anesthesiology practices, entering into price-setting agreements with independent practices, and agreeing with a competitor to stay out of a USAP territory. Although WCAS owns less than 25% of USAP today, the FTC has sued the private equity investor and alleged that the investor played an instrumental role in developing USAP's horizontal acquisition strategy, particularly with respect to mergers and acquisitions of anesthesia practices in Texas.

Under the Biden administration, FTC and the Department of Justice, Antitrust Division (DOJ)(together, the Agencies), have been focused on consolidation by private equity, particularly with respect to "roll-ups," which are serial acquisitions of provider practices in the same or adjacent geographic areas.

The FTC's action is consistent with the Agencies' continued focus on the healthcare industry and is the latest in a string of enforcement actions and substantial changes to federal antitrust enforcement under the Biden Administration. Among other things, the Agencies have withdrawn decades of healthcare antitrust enforcement guidance, sought to ban employee non-competes, and proposed dramatic revisions to the current merger review framework.

Private equity firms or other investors considering a roll-up strategy should consult with counsel to understand and navigate the current antitrust enforcement landscape.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More